0.00
price down icon100.00%   -3.41
after-market Dopo l'orario di chiusura: 3.41 3.41 +
loading
Precedente Chiudi:
$3.41
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$524.82M
Reddito:
$117.10K
Utile/perdita netta:
$-161.61M
Rapporto P/E:
0.00
EPS:
-2.4059
Flusso di cassa netto:
-
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
Value
$0.00
$0.00
Intervallo di 1 settimana:
Value
$0.00
$0.00
Portata 52W:
Value
$0.00
$6.30

Opthea Limited Adr Stock (OPT) Company Profile

Name
Nome
Opthea Limited Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
34
Name
Cinguettio
Name
Prossima data di guadagno
2024-09-04
Name
Ultimi documenti SEC
Name
OPT's Discussions on Twitter

Confronta OPT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
OPT
Opthea Limited Adr
0.00 524.82M 117.10K -161.61M 0 -2.4059
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.16 120.29B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
554.58 60.26B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
339.80 43.10B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.89 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
299.94 33.09B 3.81B -644.79M -669.77M -6.24

Opthea Limited Adr Stock (OPT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-03-25 Downgrade H.C. Wainwright Buy → Neutral
2025-03-25 Downgrade Jefferies Buy → Underperform
2025-03-25 Downgrade Leerink Partners Outperform → Market Perform
2025-03-24 Downgrade Oppenheimer Outperform → Perform
2022-12-08 Iniziato H.C. Wainwright Buy
2022-04-26 Iniziato SVB Leerink Outperform
2020-11-17 Iniziato Citigroup Buy
2020-11-11 Iniziato Oppenheimer Outperform
2020-11-11 Iniziato SVB Leerink Outperform
2020-11-11 Iniziato Truist Buy
Mostra tutto

Opthea Limited Adr Borsa (OPT) Ultime notizie

pulisher
Jul 26, 2025

Opthea (NASDAQ:OPT) Stock Price Up 7.2% – What’s Next? - Defense World

Jul 26, 2025
pulisher
Jul 19, 2025

Opthea Limited Depositary Receipt Stock Analysis and ForecastHigh-octane gains - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 04, 2025

Opthea (NASDAQ:OPT) Stock Price Up 7.2% – Time to Buy? - Defense World

Jul 04, 2025
pulisher
Jul 03, 2025

Opthea Limited Relocates Registered Office to Melbourne - TipRanks

Jul 03, 2025
pulisher
Jun 12, 2025

Millennium Management LLC Reduces Stock Holdings in Opthea Limited (NASDAQ:OPT) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Citadel Advisors LLC Takes $79,000 Position in Opthea Limited (NASDAQ:OPT) - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Opthea Limited (NASDAQ:OPT) Given Average Recommendation of “Hold” by Brokerages - Defense World

Jun 09, 2025
pulisher
May 24, 2025

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and ALX Oncology Holdings (ALXO) - The Globe and Mail

May 24, 2025
pulisher
May 22, 2025

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), ACADIA Pharmaceuticals (ACAD) and Quanterix (QTRX) - The Globe and Mail

May 22, 2025
pulisher
May 20, 2025

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Arcellx Inc (ACLX) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail

May 20, 2025
pulisher
May 16, 2025

Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail

May 16, 2025
pulisher
May 16, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail

May 16, 2025
pulisher
May 15, 2025

Opthea Limited (NASDAQ:OPT) Given Average Rating of “Hold” by Analysts - Defense World

May 15, 2025
pulisher
May 08, 2025

Sarepta Therapeutics (SRPT) Gets a Buy from Oppenheimer - The Globe and Mail

May 08, 2025
pulisher
May 08, 2025

Analysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ) - The Globe and Mail

May 08, 2025
pulisher
Apr 23, 2025

Brokerages Set Opthea Limited (NASDAQ:OPT) PT at $1.33 - Defense World

Apr 23, 2025
pulisher
Apr 11, 2025

Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace

Apr 11, 2025
pulisher
Apr 10, 2025

Opthea Ltd shares corporate update in SEC filing - Investing.com

Apr 10, 2025
pulisher
Apr 08, 2025

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Apr 08, 2025
pulisher
Apr 02, 2025

Opthea Announces Termination of ShORe and COAST Trials of Sozinibercept - HCPLive

Apr 02, 2025
pulisher
Mar 31, 2025

Opthea Halts Wet AMD Clinical Trials By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Opthea Halts Wet AMD Clinical Trials - Investing.com

Mar 31, 2025
pulisher
Mar 29, 2025

Opthea Limited (NASDAQ:OPT) Receives $1.33 Consensus PT from Brokerages - Defense World

Mar 29, 2025
pulisher
Mar 25, 2025

Hold Rating Issued for Opthea Limited Amid Uncertainty Following Phase 3 Trial Failure - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Opthea Limited: Hold Rating Amid Phase 3 Trial Failure and Financial Uncertainty - TipRanks

Mar 25, 2025
pulisher
Mar 24, 2025

Opthea’s COAST Phase 3 Trial Fails to Meet Primary Endpoint, Raising Financial Concerns - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Opthea COAST trial misses primary endpoint, enters talks with DFA Investors - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Opthea reports phase 3 trial results for eye treatment - Investing.com

Mar 24, 2025
pulisher
Mar 19, 2025

Promising Developments and Strong Financial Position Propel AbSci’s Growth Prospects - TipRanks

Mar 19, 2025
pulisher
Mar 10, 2025

Opthea Limited Announces New Securities Quotation on ASX - TipRanks

Mar 10, 2025
pulisher
Mar 05, 2025

Opthea Limited Reports Increased Losses Amid Clinical Advancements - TipRanks

Mar 05, 2025
pulisher
Feb 28, 2025

Optimistic Buy Rating for Opthea Limited Driven by Promising Phase 3 Trials and Innovative AMD Treatment - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Opthea reports mid-year financial results - Investing.com

Feb 28, 2025
pulisher
Feb 26, 2025

Opthea Ltd completes key drug product campaign - Investing.com

Feb 26, 2025
pulisher
Feb 20, 2025

Opthea Completes Key Phase 3 Trial Milestone in Wet AMD Treatment - TipRanks

Feb 20, 2025
pulisher
Feb 19, 2025

Opthea Limited completes week 52 patient visits in the COAST trial - Ophthalmology Times

Feb 19, 2025
pulisher
Feb 18, 2025

Optimistic Outlook and Buy Rating for Opthea Limited Amid Promising Phase 3 Trials and Strong Financial Position - TipRanks

Feb 18, 2025
pulisher
Feb 07, 2025

Opthea to Present at Oppenheimer Healthcare Conference - GlobeNewswire Inc.

Feb 07, 2025
pulisher
Feb 06, 2025

OPTOpthea Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan

Feb 06, 2025
pulisher
Jan 31, 2025

Is Opthea Limited (OPT) One of the Best ASX Stocks to Buy According to Hedge Funds? - Insider Monkey

Jan 31, 2025
pulisher
Jan 28, 2025

Opthea Unveils Promising Wet AMD Therapy at Investor Day - TipRanks

Jan 28, 2025
pulisher
Jan 27, 2025

Why Opthea (OPT) Is Among the Best Australian Stocks to Buy Now? - Yahoo Finance

Jan 27, 2025
pulisher
Jan 08, 2025

Opthea Sets Key 2025 Investor Events to Showcase Breakthrough Wet AMD Treatment Sozinibercept - StockTitan

Jan 08, 2025
pulisher
Dec 31, 2024

Opthea Limited Reports Earnings Results for the Half Year Ended December 31, 2024 - Marketscreener.com

Dec 31, 2024
pulisher
Dec 19, 2024

Opthea to Present Phase 3 Trial Update at J.P. Morgan Healthcare Conference - TipRanks

Dec 19, 2024
pulisher
Dec 18, 2024

Race Oncology bolsters leadership - The Australian

Dec 18, 2024
pulisher
Nov 25, 2024

Opthea Limited CEO to Present at Citi 2024 Global Healthcare Conference in Miami - Quiver Quantitative

Nov 25, 2024
pulisher
Nov 19, 2024

Opthea Limited Targets AMD Market with Sozinibercept - TipRanks

Nov 19, 2024
pulisher
Nov 15, 2024

Opthea Appoints Kathy Connell to Board of Directors - The Manila Times

Nov 15, 2024
pulisher
Nov 12, 2024

Opthea's Wet AMD Program Featured at Ophthalmology Events - The Manila Times

Nov 12, 2024
pulisher
Nov 04, 2024

Opthea to Participate in November Investor Conferences - The Manila Times

Nov 04, 2024

Opthea Limited Adr Azioni (OPT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$77.55
price up icon 0.23%
$37.12
price down icon 0.40%
$105.18
price up icon 0.17%
$26.66
price down icon 0.30%
$110.05
price down icon 1.28%
biotechnology ONC
$299.94
price down icon 1.90%
Capitalizzazione:     |  Volume (24 ore):